Home › Opioid Overdose › South Carolina › Greenville
Opioid Overdose clinical trials in Greenville, SC
4 studies for Opioid Overdose are looking for participants at sites in and around Greenville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
RecruitingHealthy volunteers welcome
- Challenges, Inc/Prisma Health, Greenville
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
RecruitingPhase 2
- Prisma Health, Greenville
Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine
Recruiting
- Addiction Medicine Center, Greenville
Building Retention and Initiation Through Delivery of Peer-Guided Evidence-Based Practices
Recruiting
- Prisma Health Upstate, Greenville
About Opioid Overdose
Opioid overdose leads to slowing or stopping of breathing and sometimes death. You can take steps to help prevent an overdose, and respond to one with naloxone.
More about Opioid Overdose on MedlinePlus
Opioid Overdose trials in other cities
- Baltimore, MD18 studies
- New Haven, CT17 studies
- Philadelphia, PA15 studies
- New York City, NY12 studies
- Boston, MA12 studies
- Birmingham, AL7 studies
- Salt Lake City, UT7 studies
- Pittsburgh, PA7 studies
- Charleston, SC6 studies
- San Francisco, CA6 studies
- Providence, RI6 studies
- Chicago, IL5 studies
Other studies in Greenville
- Non-Small Cell Lung Cancer15 studies
- Breast Cancer12 studies
- Acute Myeloid Leukemia10 studies
- Cancer (all types)9 studies
- Obesity9 studies
- Lung Cancer9 studies
- Overweight8 studies
- Prostate Cancer7 studies
- Colorectal Cancer7 studies
- Stomach Cancer6 studies
- Peripheral Arterial Disease5 studies
- Burkitt Lymphoma5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.